Novartis Confirms Acquisition of Allergy-Drug Developer Excellergy for Up to $2 Billion

Novartis has confirmed its intention to acquire Excellergy, an allergy-drug developer, in a deal valued at up to $2 billion, with the Wall Street Journal providing further details and confirmation on the acquisition.